James W. Blasetto
About
James W. Blasetto is a scholar working on Surgery, Economics and Econometrics and Endocrinology, Diabetes and Metabolism.
According to data from OpenAlex, James W. Blasetto has authored 22 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Surgery, 13 papers in Economics and Econometrics and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in James W. Blasetto's work include Lipoproteins and Cardiovascular Health (19 papers), Health Systems, Economic Evaluations, Quality of Life (11 papers) and Pharmaceutical Economics and Policy (8 papers). James W. Blasetto is often cited by papers focused on Lipoproteins and Cardiovascular Health (19 papers), Health Systems, Economic Evaluations, Quality of Life (11 papers) and Pharmaceutical Economics and Policy (8 papers). James W. Blasetto collaborates with scholars based in United States, United Kingdom and South Africa. James W. Blasetto's co-authors include Evan A. Stein, Valerie A. Cain, Peter H. Jones, James M. McKenney, Harold Bays, Elinor Miller, Michael H. Davidson, W. Virgil Brown, Rohini Chitra and Ali Raza and has published in prestigious journals such as The American Journal of Cardiology, American Heart Journal and Atherosclerosis.
In The Last Decade
James W. Blasetto
21 papers receiving 1.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| James W. Blasetto United States | 12 | 1.5k | 647 | 635 | 397 | 298 | 22 | 1.8k | ||
| Elinor Miller United States | 11 | 1.4k 0.9× | 567 0.9× | 599 0.9× | 352 0.9× | 282 0.9× | 19 | 1.7k | ||
| Irene Laurora United States | 6 | 1.4k 0.9× | 579 0.9× | 756 1.2× | 264 0.7× | 372 1.2× | 13 | 1.8k | ||
| Joanne Palmisano United States | 19 | 1.9k 1.2× | 805 1.2× | 661 1.0× | 447 1.1× | 652 2.2× | 30 | 2.6k | ||
| Phillip D. Toth United States | 11 | 1.3k 0.8× | 586 0.9× | 382 0.6× | 254 0.6× | 231 0.8× | 25 | 1.8k | ||
| Lorenzo Melani Italy | 19 | 1.7k 1.1× | 554 0.9× | 530 0.8× | 665 1.7× | 448 1.5× | 28 | 2.3k | ||
| José Luis Zamorano Spain | 9 | 1.6k 1.1× | 781 1.2× | 595 0.9× | 302 0.8× | 787 2.6× | 16 | 2.4k | ||
| Alexandre LeBeaut United States | 14 | 1.6k 1.1× | 530 0.8× | 469 0.7× | 642 1.6× | 315 1.1× | 24 | 2.3k | ||
| Eli M. Roth United States | 24 | 2.1k 1.4× | 587 0.9× | 781 1.2× | 315 0.8× | 586 2.0× | 60 | 2.7k | ||
| Amy O. Johnson‐Levonas United States | 28 | 1.3k 0.8× | 801 1.2× | 333 0.5× | 416 1.0× | 344 1.2× | 89 | 2.4k | ||
| Jonathan L. Isaacsohn United States | 22 | 1.5k 1.0× | 725 1.1× | 266 0.4× | 289 0.7× | 582 2.0× | 50 | 2.4k |
Countries citing papers authored by James W. Blasetto
Since
Specialization
Citations
This map shows the geographic impact of James W. Blasetto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James W. Blasetto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James W. Blasetto more than expected).
Fields of papers citing papers by James W. Blasetto
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by James W. Blasetto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James W. Blasetto. The network helps show where James W. Blasetto may publish in the future.
Co-authorship network of co-authors of James W. Blasetto
This figure shows the co-authorship network connecting the top 25 collaborators of James W. Blasetto. A scholar is included among the top collaborators of James W. Blasetto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James W. Blasetto. James W. Blasetto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Roth, Eli M., Robert S. Rosenson, Dawn M. Carlson, et al.. (2010). Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study. Cardiovascular Drugs and Therapy. 24(5-6). 421–428.
2.
Shepherd, James, Donald G. Vidt, Elinor Miller, Susan S. Harris, & James W. Blasetto. (2007). Safety of Rosuvastatin: Update on 16,876 Rosuvastatin-Treated Patients in a Multinational Clinical Trial Program. Cardiology. 107(4). 433–443.
3.
Fox, Kathleen M., Sanjay Gandhi, Robert L. Ohsfeldt, James W. Blasetto, & Harold Bays. (2007). Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL‑C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Current Medical Research and Opinion. 23(9). 2125–2133.
4.
Harley, Carolyn, et al.. (2007). Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. The American journal of geriatric pharmacotherapy. 5(3). 185–194.
5.
Fox, Kathleen M., Sanjiv K. Gandhi, Robert L. Ohsfeldt, James W. Blasetto, & Michael H. Davidson. (2007). Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data*. International Journal of Clinical Practice. 61(10). 1634–1642.
6.
Fox, Kathleen M., Sanjay Gandhi, Robert L. Ohsfeldt, James W. Blasetto, & Michael H. Davidson. (2007). Titration patterns with rosuvastatin as compared with other statins in clinical practice: A retrospective observational cohort study using an electronic medical record database. Clinical Therapeutics. 29(11). 2385–2394.
7.
Marais, A. David, Frederick J. Raal, Evan A. Stein, et al.. (2007). A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 197(1). 400–406.
8.
Deedwania, Prakash, Donald B. Hunninghake, Harold Bays, et al.. (2005). Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. The American Journal of Cardiology. 95(3). 360–366.
9.
Shepherd, James, Chris J. Packard, Thomas Littlejohn, et al.. (2004). Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy*. Current Medical Research and Opinion. 20(10). 1571–1578.
10.
Jones, Peter M., D B Hunninghake, Keith C. Ferdinand, et al.. (2004). Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clinical Therapeutics. 26(9). 1388–1399.
11.
Caplan, Richard, et al.. (2004). More Western Hypercholesterolemic Patients Achieve Japan Atherosclerosis Society LDL-C Goals With Rosuvastatin Therapy Than With Atorvastatin, Pravastatin, or Simvastatin Therapy. Circulation Journal. 68(2). 107–113.
12.
Stender, Steen, et al.. (2004). M.458 Effects of switching statins on non-HDL-C in hypercholesterolaemic patients and achievement of ATP III combined LDL-C and non-HDL-C goals in patients with elevated triglycerides: Mercury I trial results. Atherosclerosis Supplements. 5(1). 106–106.
13.
Blasetto, James W., Evan A. Stein, W. Virgil Brown, Rohini Chitra, & Ali Raza. (2003). Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. The American Journal of Cardiology. 91(5). 3–10.
14.
Ballantyne, Christie M., Evan A. Stein, Rodolfo Paoletti, Harry Southworth, & James W. Blasetto. (2003). Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. The American Journal of Cardiology. 91(5). 25–27.
15.
Schuster, H., et al.. (2003). 1P-0281 Switching to rosuvastatin from other statins has beneficial effects on lipid ratios. Atherosclerosis Supplements. 4(2). 81–81.
16.
McKenney, James M., Peter H. Jones, Maciej Adamczyk, et al.. (2003). Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Current Medical Research and Opinion. 19(8). 689–698.
17.
Jones, Peter H., Michael H. Davidson, Evan A. Stein, et al.. (2003). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial). The American Journal of Cardiology. 92(2). 152–160.
18.
Blasetto, James W.. (1997). Health Problems Related to Cigarette Smoke. NEW SOLUTIONS A Journal of Environmental and Occupational Health Policy. 6(4). 39–44.
19.
Doorey, Andrew J., et al.. (1994). Usefulness of magnetic resonance imaging for diagnosing an anomalous coronary artery coursing between aorta and pulmonary trunk. The American Journal of Cardiology. 74(2). 198–199.
20.
Blasetto, James W., James S. Donahoo, & John Shuck. (1988). Single coronary artery in association with anomalous right ventricular muscle bundles. American Heart Journal. 115(5). 1122–1124.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Elinor Miller Breakdown of academic impact, for papers by Irene Laurora Breakdown of academic impact, for papers by Joanne Palmisano Breakdown of academic impact, for papers by Phillip D. Toth Breakdown of academic impact, for papers by Lorenzo Melani Breakdown of academic impact, for papers by José Luis Zamorano Breakdown of academic impact, for papers by Alexandre LeBeaut Breakdown of academic impact, for papers by Eli M. Roth Breakdown of academic impact, for papers by Amy O. Johnson‐Levonas Breakdown of academic impact, for papers by Jonathan L. Isaacsohn